This case analyzes Millennium's organizational and tactical reactions to the fast development of the biopharmaceutical market. In the early 2000s, as Millennium's competitive benefit in early-stage research study escaped and its losses installed, creator and CEO Mark Levin moved the company downstream far from research study and to drug advancement and commercialization, besides contracting horizontal breadth from over a dozen therapeutic classes to merely three.
Organization and Strategy at Millennium (A) Case Study Solution
In year 2005, Levin worked with Deborah Dunsire from Novartis as CEO to direct Millennium's continuing alteration. Students are appealed to put themselves in the shoes of inbound CEO Dunsire and to offer organizational suggestions to carry out the brand-new strategy.
PUBLICATION DATE: February 02, 2010 PRODUCT #: 710415-PDF-ENG
This is just an excerpt. This case is about STRATEGY & EXECUTION
Related Case Solutions & Analyses:
Regulatory Uncertainty and Corporate Responses to Environmental Protection in China
SecondMarket – Providing Liquidity for Shareholders of Privately Held iContact
Systems Infrastructure at Google (B)
Bank of America-Merrill Lynch
Negotiating for the Motion Picture Association of America and the Motion Picture Association: Jack Valenti (A)
Bond Ratings
ZipCar
Can You Buy CSR?
Medical Technology Industry and Japan (A)
THESIS
